Dose Finding Study of BI 836880 in Patients With Solid Tumors

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

29 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-05

Study Completion Date

2020-11-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase I, non-randomized, uncontrolled, open-label, dose escalating study of BI 836880 administered intravenously. The eligible patient population will be patients with advanced solid tumours. At any time during the trial, it will not be permitted to escalate to a dose which does not fulfil the escalation with overdose control (EWOC) criterion

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Weekly BI 836880 in Patients With Advanced Solid Tumors

NCT02689505

Neoplasms

COMPLETED PHASE1

BI 811283 in Various Solid Tumours

NCT00701324

Neoplasms

COMPLETED PHASE1

Phase I Study of BI 831266 in Patients With Advanced Solid Tumours

NCT00756223

Neoplasms

COMPLETED PHASE1

Monotherapy Dose Finding With BI 847325 in Solid Tumours

NCT01324830

Neoplasms

COMPLETED PHASE1

BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours

NCT02273388

Neoplasms

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

40 mg BI 836880

BI 836880

Group Type EXPERIMENTAL

BI 836880

Intervention Type DRUG

BI 836880

120 mg BI 836880

BI 836880

Group Type EXPERIMENTAL

BI 836880

Intervention Type DRUG

BI 836880

360 mg BI 836880

BI 836880

Group Type EXPERIMENTAL

BI 836880

Intervention Type DRUG

BI 836880

720 mg BI 836880

BI 836880

Group Type EXPERIMENTAL

BI 836880

Intervention Type DRUG

BI 836880

1000 mg BI 836880

BI 836880

Group Type EXPERIMENTAL

BI 836880

Intervention Type DRUG

BI 836880

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 836880

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>= 18 years
* Histologically or cytologically confirmed malignancy which is locally advanced or metastatic solid tumor, and either refractory after standard therapy for the disease or for which standard therapy is not reliably effective, e.g. they do not tolerate or have contraindications to otherwise available standard therapy and tumour lesions evaluable for Dynamic contrast-enhanced (DCE)-MRI at MTD.
* ECOG performance status \<= 2
* Adequate hepatic, renal and bone marrow functions
* Signed written informed consent.
* Life expectancy min. 3 months in the opinion of the investigator
* Recovery from all reversible adverse events of previous anti-cancer therapies to baseline or CTCAE grade 1, except for alopecia (any grade) sensory peripheral neuropathy CTCAE grade \<= 2 or considered not clinically significant.
* adequate contraception by male and female patient during the trial and for at least 6 months after end of treatment.

Exclusion Criteria

* Known hypersensitivity to the trial drugs or their excipients
* Current or prior treatment with any systemic anti-cancer therapy either within 28 days or a minimum of 5 half-lives, whichever is shorter of trial onset.
* Serious concomitant disease, especially those affecting compliance with trial requirements or which are considered relevant for the evaluation of the endpoints of the trial drug
* Major injuries and/or surgery or bone fracture within 4 weeks of start of treatment, or planned surgical procedures during the trial period.
* patients with personal or family history of QT prolongation and/or long QT syndrome, or prolonged QTcF at baseline (\> 470 ms). QTcF will be calculated by Investigator as the mean of the 3 ECGs taken at screening.
* Significant cardiovascular/cerebrovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 6 months, congestive heart failure \> NYHA II). Uncontrolled hypertension defined as: blood pressure in rested and relaxed condition \>=140 mmHg systolic, or \>=90 mmHg diastolic (with or without medication), measured according to protocol.
* History of severe haemorrhagic or thromboembolic event in the past 12 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis).
* Known inherited predisposition to bleeding or to thrombosis in the opinion of the investigator.
* Patient with brain metastases that are symptomatic and/or require therapy.
* Patients who require full-dose anticoagulation (according to local guidelines).
* Active alcohol or drug abuse in the opinion of the investigator.
* Patients who are under judicial protection and patients who are legally institutionalized.
* Patients unable or unwilling to comply with protocol
* Women who are pregnant, nursing, or who plan to become pregnant while in the trial

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No